Strategies to Make Revolutionary Cellular Therapies Even More Robust Neff Newitt, Valerie Neff Newitt, Valerie Less Oncology Times. 45(11):1,10-11, June 5, 2023. Favorite PDF Permissions Free
Pirtobrutinib (Jaypirca™) McCabe, Mikaela McCabe, Mikaela Less Oncology Times. 45(10):13, May 20, 2023. Favorite PDF Permissions Free
Lymphoma Tumor Model Opens Avenues for New Therapies Less Oncology Times. 45(9):1,10, May 5, 2023. Favorite PDF Permissions Free
Boosting the Development of Next-Generation Cell Therapies Eastman, Peggy Eastman, Peggy Less Oncology Times. 45(8):17-18, April 20, 2023. Favorite PDF Permissions Free
In-House Technology Used to Expedite Delivery of CAR-T Therapy Froelich, Warren Froelich, Warren Less Oncology Times. 45(8):1,10, April 20, 2023. Favorite PDF Permissions Free
Key Molecule in Progression of Chronic Myeloproliferative Neoplasms Kumar Das, Dibash Kumar Das, Dibash Less Oncology Times. 45(7):20, April 5, 2023. Favorite PDF Permissions Free
Improving Access: The Best Therapies Only Work If Patients Can Get Them Neff Newitt, Valerie Neff Newitt, Valerie Less Oncology Times. 45(7):14-15, April 5, 2023. Favorite PDF Permissions Free
Mosunetuzumab-Axgb Approved for R/R Follicular Lymphoma Kumar Das, Dibash Kumar Das, Dibash Less Oncology Times. 45(6):1,9, March 20, 2023. Favorite PDF Permissions Free
CAR T-Cell Therapy in Patients With Lymphoma of the Brain & Spinal Cord Less Oncology Times. 45(2):13, January 20, 2023. Favorite PDF Permissions Free
New Regimen Reduces Relapse in Aggressive T-Cell Malignancies Fuerst, Mark L. Fuerst, Mark L. Less Oncology Times. 45(1):1,19, January 5, 2023. Favorite PDF Permissions Free
NCCN Highlights New Treatment Advances in Blood Cancer Holt, Chuck Holt, Chuck Less Oncology Times. 44(23):1,17, December 5, 2022. Favorite PDF Permissions Free
Loncastuximab Tesirine-lpyl (Zynlonta®) Shultes, Kendall C. Shultes, Kendall C. Less Oncology Times. 44(22):14, November 20, 2022. Favorite PDF Permissions Free
Lymphoma Helpline Offers Support to Patients & Caregivers Nalley, Catlin Nalley, Catlin Less Oncology Times. 44(21):21, November 5, 2022. Favorite PDF Permissions Free
Brentuximab Vedotin Improves Overall Survival in Stage III/IV Hodgkin Lymphoma Kumar Das, Dibash Kumar Das, Dibash Less Oncology Times. 44(20):1,9, October 20, 2022. Favorite PDF Permissions Free
Synthetic Hypericin Photodynamic Therapy for Cutaneous T-Cell Lymphoma Kumar Das, Dibash Kumar Das, Dibash Less Oncology Times. 44(20):1,7, October 20, 2022. Favorite PDF Permissions Free
Real-World Outcomes Versus Clinical Trials for Mantle Cell Lymphoma Kumar Das, Dibash Kumar Das, Dibash Less Oncology Times. 44(18):11-12, September 20, 2022. Favorite PDF Permissions Free CME Test
Potential Precision Therapies in Diffuse Large B-Cell Lymphoma Kumar Das, Dibash Kumar Das, Dibash Less Oncology Times. 44(18):1,9, September 20, 2022. Favorite PDF Permissions Free
Brexucabtagene Autoleucel (Tecartus™) Lovell, Alexandra Lovell, Alexandra Less Oncology Times. 44(16):10, August 20, 2022. Favorite PDF Permissions Free
The Arrival of CAR T-Cell Therapy for R/R Follicular Lymphoma Kumar Das, Dibash Kumar Das, Dibash Less Oncology Times. 44(16):1,9, August 20, 2022. Favorite PDF Permissions Free
Addressing Disparities in CAR T-Cell Therapy Trials Kumar Das, Dibash Kumar Das, Dibash Less Oncology Times. 44(14):1,12, July 20, 2022. Favorite PDF Permissions Free
Phase III Belinda Study for Aggressive B-Cell Lymphoma Kumar Das, Dibash Kumar Das, Dibash Less Oncology Times. 44(13):1,7,10, July 5, 2022. Favorite PDF Permissions Free
A Novel Therapeutic Target for Diffuse Large B-Cell Lymphomas Kumar Das, Dibash Kumar Das, Dibash Less Oncology Times. 44(11):1,25, June 5, 2022. Favorite PDF Permissions Free
Cancer Immunotherapy During Pregnancy for Relapsed Lymphoma Evens, Andrew M. Evens, Andrew M. Less Oncology Times. 44(11):1,16, June 5, 2022. Favorite PDF Permissions Free
NK Cells + Bispecific Antibody Improved Response in Lymphoma Patients Froelich, Warren Froelich, Warren Less Oncology Times. 44(10):27, May 20, 2022. Favorite PDF Permissions Free
Key Genomic Alterations in Cutaneous T-Cell Lymphoma Less Oncology Times. 44(8):1,23, April 20, 2022. Favorite PDF Permissions Free
HIV Not Likely to Result in T-Cell Lymphoma Nolen, Lindsey Nolen, Lindsey Less Oncology Times. 43(24):1,19, December 20, 2021. Favorite PDF Permissions Free
Umbralisib (Ukoniq™) Lovell, Alexandra Lovell, Alexandra Less Oncology Times. 43(21):13, November 5, 2021. Favorite PDF Permissions Free
Advances in Off-the-Shelf Immunotherapy: Expert Discussion Kumar Das, Dibash Kumar Das, Dibash Less Oncology Times. 43(19):12-13, October 5, 2021. Favorite PDF Permissions Free CME Test
CAR T-Cell Therapy Emerges as Option in Follicular Lymphoma Schneider, Mary Ellen Schneider, Mary Ellen Less Oncology Times. 43(18):1,8, September 20, 2021. Favorite PDF Permissions Free
Subcutaneous Epcoritamab for B-Cell Non-Hodgkin Lymphoma Nalley, Catlin Nalley, Catlin Less Oncology Times. 43(17):28, September 5, 2021. Favorite PDF Permissions Free
Blood Cancer Patients With COVID-19 Fare Better With Convalescent Plasma Less Oncology Times. 43(13):1,12, July 5, 2021. Favorite PDF Permissions Free
Protein Found to Control Drivers of Normal Growth & Cancer Less Oncology Times. 43(12):1,13, June 20, 2021. Favorite PDF Permissions Free
Copanlisib Combination Cuts Lymphoma Progression by Nearly Half Samson, Kurt Samson, Kurt Less Oncology Times. 43(10):1,18, May 20, 2021. Favorite PDF Permissions Free
New CAR-T Approach Minimizes Resistance in B-Cell Lymphoma Less Oncology Times. 43(9):1,21, May 5, 2021. Favorite PDF Permissions Free
Peripheral T-Cell Lymphoma: Treatment & Stratification of Risk & Prognosis Simoneaux, Richard Simoneaux, Richard Less Oncology Times. 43(8):1,13-14, April 20, 2021. Favorite PDF Permissions Free
Lymphoma Patients at Higher Risk of Death When Diagnosed With COVID-19 Froelich, Warren Froelich, Warren Less Oncology Times. 43(7):35, April 5, 2021. Favorite PDF Permissions Free
Novel Agents Show Promise in Diffuse Large B-Cell Lymphoma Fuerst, Mark L. Fuerst, Mark L. Less Oncology Times. 43(7):32, April 5, 2021. Favorite PDF Permissions Free
CARs Are the Ride of the Future for Curing DLBCL Fuerst, Mark L. Fuerst, Mark L. Less Oncology Times. 43(7):31, April 5, 2021. Favorite PDF Permissions Free
Burkitt Lymphoma: An International Prognostic Index Evens, Andrew M. Evens, Andrew M. Less Oncology Times. 43(7):1,10-11, April 5, 2021. Favorite PDF Permissions Free
Advances in the Treatment of Patients With R/R Follicular Lymphoma Kumar Das, Dibash Kumar Das, Dibash Less Oncology Times. 43(6):1,11, March 20, 2021. Favorite PDF Permissions Free
Scientists Create On-Off Switches to Control CAR T-Cell Activity Less Oncology Times. 43(4):1,12, February 20, 2021. Favorite PDF Permissions Free
The Discovery of a Potent Weapon Against Lymphomas Less Oncology Times. 43(3):28, February 5, 2021. Favorite PDF Permissions Free
3 QUESTIONS ON... How to Better Manage Late Effects for Survivors of Hodgkin Lymphoma: With Andrew Evens, DO, MSc, of Rutgers Cancer Institute of New Jersey DiGiulio, Sarah DiGiulio, Sarah Less Oncology Times. 42(24):98, December 20, 2020. Favorite PDF Permissions Free
A New Strategy in Treating Patients With CAR T-Cell Therapy Jenks, Susan Jenks, Susan Less Oncology Times. 42(24):34, December 20, 2020. Favorite PDF Permissions Free
Potential New Standard for High-Risk B-Cell Non-Hodgkin Lymphoma Kumar Das, Dibash Kumar Das, Dibash Less Oncology Times. 42(24):1,3,14, December 20, 2020. Favorite PDF Permissions Free
Study Shows Many Non-Hodgkin Lymphoma Patients Can Skip Radiation Less Oncology Times. 42(21):26, November 5, 2020. Favorite PDF Permissions Free
Cell Therapy Ascends: New Hope for Combating Mantle Cell Lymphoma Neff Newitt, Valerie Neff Newitt, Valerie Less Oncology Times. 42(20):1,14,15,38, October 20, 2020. Favorite PDF Permissions Free
Overcoming the Challenge of Cytokine Release Syndrome in CAR T-Cell Therapy Bennett, Christina Bennett, Christina Less Oncology Times. 42(20):1,10, October 20, 2020. Favorite PDF Permissions Free
Examining Gene Mutations in Mantle Cell Lymphoma Patients Froelich, Warren Froelich, Warren Less Oncology Times. 42(19):34, October 5, 2020. Favorite PDF Permissions Free
Identifying Disparities in Adolescent & Young Adult Lymphoma Survivors Froelich, Warren Froelich, Warren Less Oncology Times. 42(19):33,37, October 5, 2020. Favorite PDF Permissions Free
New Scoring System Helps Stratify Mantle Cell Lymphoma Patients Fuerst, Mark L. Fuerst, Mark L. Less Oncology Times. 42(18):22, September 20, 2020. Favorite PDF Permissions Free
Lymphoma Takes a Different Route to Development Less Oncology Times. 42(9):1,7, May 5, 2020. Favorite PDF Permissions Free
CD19 CAR NK-Cell Therapy in Leukemia & Lymphoma Less Oncology Times. 42(5):35, March 5, 2020. Favorite PDF Permissions Free
Novel Targeted Therapies for Blastic Plasmacytoid Dendritic Cell Neoplasm Pemmaraju, Naveen Pemmaraju, Naveen Less Oncology Times. 42(1):1,11-12, January 5, 2020. Favorite PDF Permissions Free
Identifying Mechanisms of Resistance to ABT-199 in Lymphomas May, Brandon May, Brandon Less Oncology Times. 41(15):9, August 5, 2019. Favorite PDF Permissions Free
A New Approach to Spur the Immune System to Attack Lymphoma Less Oncology Times. 41(15):1,7, August 5, 2019. Favorite PDF Permissions Free
Recent Developments in the Treatment of Mantle Cell Lymphoma Simoneaux, Richard Simoneaux, Richard Less Oncology Times. 41(15):1,5-6, August 5, 2019. Favorite PDF Permissions Free
Why Advances in Immunotherapy Mean the Golden Age of Oncology Landau, Daniel Landau, Daniel Less Oncology Times. 41(13):24,32, July 5, 2019. Favorite PDF Permissions Free
Recent Developments in the Treatment of Follicular Lymphoma Simoneaux, Richard Simoneaux, Richard Less Oncology Times. 41(11):8-10, June 5, 2019. Favorite PDF Permissions Free CME Test
Why Lymphoma Patients Become Resistant to Specific Therapy Less Oncology Times. 41(11):1,12, June 5, 2019. Favorite PDF Permissions Free
Umbralisib Shows Encouraging Potential in Marginal Zone Lymphoma Samson, Kurt Samson, Kurt Less Oncology Times. 41(10):38, May 20, 2019. Favorite PDF Permissions Free
Gene Sequencing & the Follicular Lymphoma Tumor Microenvironment Hepp, Rebecca Hepp, Rebecca Less Oncology Times. 41(6):1,4, March 20, 2019. Favorite PDF Permissions Free
Characterizing the Mechanism of Action of CAR T Cells Less Oncology Times. 41(5):1,5, March 5, 2019. Favorite PDF Permissions Free
Novel Therapies to Increase Durable Remission Rates for T-Cell Lymphoma Neff Newitt, Valerie Neff Newitt, Valerie Less Oncology Times. 40(23):1,6-7, December 5, 2018. Favorite PDF Permissions Free
Prevalent Epigenetic Modifier Mutations Found in Follicular Lymphoma Simoneaux, Richard Simoneaux, Richard Less Oncology Times. 40(22):1,8-9, November 20, 2018. Favorite PDF Permissions Free
Genomic Analysis Unravels the Many Complexities of DLBCL Less Oncology Times. 40(19):39, October 5, 2018. Favorite PDF Permissions Free
Utilizing Acalabrutinib Alone or in Combination for Follicular Lymphoma Nalley, Catlin Nalley, Catlin Less Oncology Times. 40(19):38, October 5, 2018. Favorite PDF Permissions Free
Blood Test Predicts Lymphoma Therapy Success Within Days Less Oncology Times. 40(18):1,4-5, September 20, 2018. Favorite PDF Permissions Free
Applying Genomics to Leukemias & Lymphomas Parikh, Ankur R. Parikh, Ankur R. Less Oncology Times. 40(17):1,2,3,4,8, September 5, 2018. Favorite PDF Permissions Free
Evaluating CAR-T Therapy in Patients With Refractory B-Cell Lymphomas Simoneaux, Richard Simoneaux, Richard Less Oncology Times. 40(15):1,8-9, August 5, 2018. Favorite PDF Permissions Free CME Test
Advances in the Systemic Management of Follicular Lymphoma Tan, Alan Tan, Alan Less Oncology Times. 40(14):1,5,6,19, July 20, 2018. Favorite PDF Permissions Free
The Ibrutinib-Venetoclax Combination in Mantle Cell Lymphoma Simoneaux, Richard Simoneaux, Richard Less Oncology Times. 40(13):1,9,13, July 5, 2018. Favorite PDF Permissions Free
Genomic Analysis of Diffuse Large B-Cell Lymphoma Less Oncology Times. 40(10):8, May 20, 2018. Favorite PDF Permissions Free
‘Excellence in Oncology’ Winner: Earning Praise for CAR T-Cell Therapy Holt, Chuck Holt, Chuck Less Oncology Times. 40(10):1,9-10, May 20, 2018. Favorite PDF Permissions Free
NCI Study Revises Molecular Classification for Most Common Lymphoma Less Oncology Times. 40(9):1-2, May 5, 2018. Favorite PDF Permissions Free
A+AVD vs. ABVD in Hodgkin Lymphoma: A Comparison of Toxicities Greenwell, I. Brian; Cohen, Jonathon B. Greenwell, I. Brian; Cohen, Jonathon B. Less Oncology Times. 40(6):1,5,8, March 20, 2018. Favorite PDF Permissions Free
Mogamulizumab Outperforms Vorinostat in Previously Treated CTCL Patients Fuerst, Mark L. Fuerst, Mark L. Less Oncology Times. 40(3):36, February 5, 2018. Favorite PDF Permissions Free
CAR T-Cell Therapy Induces Long-Lasting Responses in Refractory NHL Fuerst, Mark L. Fuerst, Mark L. Less Oncology Times. 40(3):33, February 5, 2018. Favorite PDF Permissions Free
CAR T-Cell Therapy Induces Sustained Responses in DLBCL Fuerst, Mark L. Fuerst, Mark L. Less Oncology Times. 40(3):29, February 5, 2018. Favorite PDF Permissions Free
Immunotherapy Shows Promise in Treatment of Hodgkin Lymphoma Nalley, Catlin Nalley, Catlin Less Oncology Times. 40(2):1,12, January 20, 2018. Favorite PDF Permissions Free
Genetic Link Between the Immune System & Lymphoma Less Oncology Times. 39(24):1,9, December 25, 2017. Favorite PDF Permissions Free
3 Questions on...Why Bone Marrow Biopsies May Not Be Needed for Patients in Clinical Trials: With Sarah Rutherford, MD, in the Division of Hematology & Medical Oncology at Weill Cornell Medicine DiGiulio, Sarah DiGiulio, Sarah Less Oncology Times. 39(21):40, November 10, 2017. Favorite PDF Permissions Free
Triplet Therapy Safe & Highly Active in Patients With Advanced Disease Less Oncology Times. 39(21):37, November 10, 2017. Favorite PDF Permissions Free
Phase II Study Suggests Tazemetostat Beneficial in Relapsed/Refractory Less Oncology Times. 39(21):35-36, November 10, 2017. Favorite PDF Permissions Free
Study Shows Immunologic Doublet Active Among Relapsed Patients Nalley, Catlin Nalley, Catlin Less Oncology Times. 39(21):31-32, November 10, 2017. Favorite PDF Permissions Free
Researchers Investigate Markers That May Help Prognostication Lindsey, Heather Lindsey, Heather Less Oncology Times. 39(21):29-30, November 10, 2017. Favorite PDF Permissions Free
Phase II Trial Shows Efficacy of Potential Oral Therapy Green, Chuck Green, Chuck Less Oncology Times. 39(21):27-28, November 10, 2017. Favorite PDF Permissions Free
PI3K Inhibitor Shows Promise for Patients With Relapsed/Refractory Disease Nalley, Catlin Nalley, Catlin Less Oncology Times. 39(21):25-26, November 10, 2017. Favorite PDF Permissions Free
Many Patients Not Receiving Treatment in Rituximab Era Lindsey, Heather Lindsey, Heather Less Oncology Times. 39(21):23-24, November 10, 2017. Favorite PDF Permissions Free
Discovery of Specific Gene Could Lead to New Treatment Options Green, Chuck Green, Chuck Less Oncology Times. 39(21):21-22, November 10, 2017. Favorite PDF Permissions Free
MAGNIFY Trial Shows Durability of Lenalidomide & Rituximab May, Brandon May, Brandon Less Oncology Times. 39(21):17-18, November 10, 2017. Favorite PDF Permissions Free
Circulating Cell-Free DNA May Enhance TMTV Prognostication Lindsey, Heather Lindsey, Heather Less Oncology Times. 39(21):15-16, November 10, 2017. Favorite PDF Permissions Free
Autologous HSCT Confers Greater Survival Benefit Over Allogeneic Option May, Brandon May, Brandon Less Oncology Times. 39(21):13-14, November 10, 2017. Favorite PDF Permissions Free
Idelalisib Effective Among Patients With Early Progression Nalley, Catlin Nalley, Catlin Less Oncology Times. 39(21):11-12, November 10, 2017. Favorite PDF Permissions Free
Follicular Lymphoma Treatment Strategies Continue to Evolve, Unmet Needs Remain Neff Newitt, Valerie Neff Newitt, Valerie Less Oncology Times. 39(21):2-10, November 10, 2017. Favorite PDF Permissions Free
Rituximab/Hyaluronidase (Rituxan Hycela™) Melaragno, Adam Melaragno, Adam Less Oncology Times. 39(20):18, October 25, 2017. Favorite PDF Permissions Free
Obinutuzumab Granted Priority Review for Follicular Lymphoma Less Oncology Times. 39(18):49, September 25, 2017. Favorite PDF Permissions Free
Longer Nivolumab Response Reported in Hodgkin Lymphoma Patients Samson, Kurt Samson, Kurt Less Oncology Times. 39(15):1,14,15,18, August 10, 2017. Favorite PDF Permissions Free
Copanlisib Given Priority Review Designation for Follicular Lymphoma Less Oncology Times. 39(12):33, June 25, 2017. Favorite PDF Permissions Free
Evolving Treatment Strategies for Mantle Cell Lymphoma Fakhri, Bita; Kahl, Brad Fakhri, Bita; Kahl, Brad Less Oncology Times. 39(11):1,16,27, June 10, 2017. Favorite PDF Permissions Free
